Across TCGA pan-cancer cohorts, LINC00620 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LINC00620’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where LINC00620 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00620 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

PAAD, LUSC, and HNSC are the cancer types where LINC00620 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC00620 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	Male	All	+0.120	.026	2	view →
LUSC	Male	All	−0.037	.026	1	view →
HNSC	All	III,IV	+0.022	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LINC00620 RNA expression & survival · all LINC00620 data types